Authors


Murtaza Adam, MD

Latest:

A case of a 79-year-old pseudophakic patient with AMD and rapidly progressing GA

The final case is presented by Dr Adam, showcasing a 79-year old patient with multiple diagnoses and rapid progression of geographic atrophy.


Sheryl Stevenson

Latest:

CTS 2025: Christine Kay, MD, on OPGx-LCA5 clinical results translated into real-life changes

Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.


John H. Merey, MD

Latest:

Ophthalmologist shares his story on Holocaust Remembrance Day

John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.


Ethan James

Latest:

Can AI explain AMD to patients?

Patients weigh in on the value of provider communication.


Caesar K. Luo, MD, FACS, FASRS

Latest:

Searching for durable therapies for diabetic macular edema amid the pandemic

Patients’ reluctance to visit a clinic during the COVID-19 pandemic is pushing retina specialists to optimize therapy.


Kassi Filkins

Latest:

Retina roundup: August 25 to August 29

Catch up on this week's highlights in retina.



Sumit Sharma, MD

Latest:

Improving vitrectomy outcomes and patient care in academic and private settings

Reliable visualization tools, especially those indicated for ocular use, are crucial for success.


Albert J. Augustin, MD

Latest:

Optimizing Care For Patients With Retinal Disorders

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.


Michael A. Singer, MD

Latest:

Exploring cryopreserved amniotic membrane following intravitreal injection

CAM encourages corneal healing in patients with ocular surface disease.


David Lally, MD

Latest:

Sustained-release anti-inflammatory therapy is valuable in noninfectious uveitis

Long-term sustained-release therapy pays off in management of chronic, vision-threatening disease.



John Kitchens, MD

Latest:

Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.


Carolyn Majcher, OD, FAAO

Latest:

DR/DME: Ongoing Clinical Trials and New Diagnostic Tools

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).


Alessandro Berni, MD

Latest:

New guidelines boost choriocapillaris imaging in AMD with SS-OCTA

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.


Advertorial

Latest:

Broadening the benefits of iCare EIDON retinal imaging with the new Ultra-Wide Field Module

This article is produced by iCare Finland for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.



Louis Cicchini, PhD

Latest:

The future promise of advanced therapies in ophthalmology

Cell and gene therapies in development for unmet needs.


Fred Crawford, MD

Latest:

Successful treatment of bilateral diffuse Uveal melanocytic proliueration with plasmapheresis

Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.


Patrizia Busatto, MD

Latest:

IOL designed for AMD offers hope for patients

Examining an intraocular implant that can sharpen vision for patients as disease progresses.


Dilsher S. Dhoot, MD

Latest:

Q&A: A look at suprachoroidal avoralstat with Dilsher S. Dhoot at ASRS 2025

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025.


Victor Gonzalez, MD

Latest:

Victor Gonzalez, MD, shares research findings on vision restoration in patients with retinitis pigmentosa

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).


Robin Vora, MD

Latest:

The future of retina: New targets and more durable solutions

Among the promising areas of retinal disease research are innovative approaches targeting pan-vascular endothelial growth factor inhibition.


Tunde Peto, MD, PhD

Latest:

Creating the best care environment for patients with diabetic eye disease

Tunde Peto, MD, PhD, discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.


Daniel F. Kiernan, MD, FACS

Latest:

Why wait? The data show administering steroids to DME patients with good vision leads to long-term success

A review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.


Mike Hennessy Sr, Founder and Chairman, MJH Life Sciences

Latest:

Saving the world: Pharmaceutical innovation in nine months

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.


Jean-Francois Korobelnik, MD

Latest:

Optimizing Care For Patients With Retinal Disorders

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.


Alan J. Franklin, MD, PhD, FASRS

Latest:

Q&A: Alan J. Franklin, MD, PhD, on postoperative methotrexate injections

Franklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.


Jennifer Lim, MD, FARVO, FASRS

Latest:

Q&A: Jennifer I. Lim, MD, shares insights from the DAVIO-2 study

The DAVIO-2 study reveals EYP-1901's potential as a 6-month treatment for neovascular AMD, matching aflibercept's vision outcomes with fewer doses.


Ashkan Abbey, MD

Latest:

Expert insights: Ashkan Abbey, MD discusses 1-year results of DAVIO-2 trial

Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.

© 2025 MJH Life Sciences

All rights reserved.